About
ORCA Therapeutics develops oncolytic virus-based immunotherapies for prostate cancer. Its lead candidate, ORCA-010, is in Phase I/IIa clinical testing in treatment-naive patients with localized prostate cancer, with the dose-escalation study being conducted in Canada.
Explore ORCA Therapeutics B.V.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.